"HLA-A3 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*03 allele family.
| Descriptor ID |
D015791
|
| MeSH Number(s) |
D12.776.395.550.489.400.030 D12.776.543.550.439.400.030 D23.050.301.500.100.400.030 D23.050.301.500.450.370.030 D23.050.705.552.100.400.030 D23.050.705.552.450.370.376
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HLA-A3 Antigen".
Below are MeSH descriptors whose meaning is more specific than "HLA-A3 Antigen".
This graph shows the total number of publications written about "HLA-A3 Antigen" by people in this website by year, and whether "HLA-A3 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HLA-A3 Antigen" by people in Profiles.
-
Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genet. 2019 01; 15(1):e1007808.
-
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014 Sep; 25(9):1735-1742.
-
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2012 May 15; 118(10):2594-602.
-
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother. 2008 Dec; 57(12):1817-25.
-
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2008 Feb 01; 14(3):797-803.